AI Tokens
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Income Statement
Quarterly Data

Eli Lilly & Co., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue 24,397 22,974 19,799 19,292 17,601 15,558 12,729 13,533 11,439 11,303 8,768 9,353 9,499 8,312 6,960 7,302 6,942 6,488 7,810 8,000 6,773 6,740 6,806
Cost of sales (3,933) (3,268) (3,577) (3,372) (3,008) (2,448) (2,224) (2,404) (2,171) (2,170) (1,674) (1,788) (1,860) (1,807) (1,627) (1,548) (1,579) (1,431) (2,072) (2,050) (1,431) (1,953) (1,879)
Gross margin 20,464 19,706 16,222 15,920 14,593 13,110 10,504 11,129 9,268 9,133 7,095 7,565 7,639 6,505 5,333 5,754 5,363 5,058 5,738 5,950 5,342 4,787 4,927
Research and development (4,247) (3,819) (3,510) (3,802) (3,466) (3,336) (2,734) (3,023) (2,734) (2,711) (2,523) (2,563) (2,409) (2,357) (1,985) (1,996) (1,803) (1,782) (1,610) (1,898) (1,705) (1,655) (1,672)
Marketing, selling, and administrative (3,125) (3,430) (2,934) (3,132) (2,741) (2,753) (2,469) (2,424) (2,100) (2,117) (1,952) (1,925) (1,804) (1,925) (1,749) (1,643) (1,614) (1,625) (1,558) (1,592) (1,578) (1,686) (1,576)
Acquired in-process research and development (4,181) (2,776) (584) (529) (656) (154) (1,572) (189) (2,826) (154) (111) (623) (2,975) (97) (105) (240) (62) (440) (166) (438) (178) (43) (312)
Asset impairment, restructuring, and other special charges (303) (703) (279) (84) (365) — (35) (344) (82) (435) — (68) — — — (38) (207) — — (105) — — (212)
Operating income 8,608 8,978 8,915 8,374 7,366 6,867 3,695 5,149 1,526 3,715 2,509 2,388 450 2,126 1,494 1,836 1,677 1,210 2,404 1,917 1,881 1,403 1,155
Other, net, income (expense) (202) 269 (65) (108) (133) (91) (239) (110) 62 (198) 27 121 (23) (37) 36 260 (111) (119) (351) (77) (636) 191 321
Income before income taxes 8,406 9,247 8,850 8,266 7,232 6,776 3,456 5,039 1,588 3,517 2,536 2,509 427 2,089 1,530 2,096 1,566 1,091 2,054 1,840 1,245 1,594 1,476
Income taxes (1,955) (2,152) (1,454) (1,628) (1,650) (1,116) (697) (629) (618) (550) (293) (319) (485) (326) (185) (159) (114) (138) (151) (114) (135) (204) (121)
Net income (loss) 6,451 7,095 7,396 6,638 5,583 5,661 2,759 4,410 970 2,967 2,243 2,190 (57) 1,763 1,345 1,938 1,452 953 1,903 1,726 1,110 1,390 1,355

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Revenue exhibits a trajectory of significant acceleration, transitioning from a stable range of approximately 6.7 billion to 8.0 billion USD between early 2021 and early 2023, to a period of rapid growth. By the third quarter of 2026, revenue is projected to reach 24.397 billion USD, representing a substantial increase in market scale. Gross margin follows a similar upward trajectory, expanding from 4.927 billion USD in March 2021 to 20.464 billion USD by September 2026, indicating that the cost of sales is not scaling linearly with revenue growth, thereby improving the overall gross profitability profile.

Operating Expense Analysis
Research and development (R&D) expenditures show a consistent and disciplined increase, rising from 1.672 billion USD in early 2021 to a projected 4.247 billion USD by September 2026. This indicates a sustained commitment to pipeline expansion. Marketing, selling, and administrative expenses have also trended upward, growing from 1.576 billion USD to 3.125 billion USD over the same period, reflecting the costs associated with scaling commercial operations.
Investment in Innovation and Acquisitions
Acquired in-process research and development (IPR&D) is characterized by extreme volatility, with periodic large-scale outlays. Notable spikes occur in September 2023 (2.975 billion USD), June 2024 (2.826 billion USD), and the second and third quarters of 2026, with the latter reaching 4.181 billion USD. These expenditures suggest an aggressive inorganic growth strategy through the acquisition of external assets and technologies.
Operating Income and Net Profitability
Operating income demonstrates an overall growth trend despite significant quarterly fluctuations caused by IPR&D and special charges. A notable contraction occurred in September 2023, where operating income dropped to 450 million USD due to high IPR&D costs. However, the trajectory recovers strongly, reaching projected levels of 8.608 billion USD by September 2026. Net income reflects this volatility, evidenced by a loss of 57 million USD in September 2023, followed by a surge toward 6.451 billion USD in the final analyzed quarter.
Taxation and Other Income
Income tax expenses have scaled in proportion to the increase in pre-tax income, rising from 121 million USD in March 2021 to a projected 1.955 billion USD by September 2026. Other net income and expenses remain relatively immaterial compared to operating results, though they contribute to minor fluctuations in the final net income figures.

The overall financial profile indicates a transition from a steady-state operation to a high-growth phase. The expansion in revenue and gross margin is partially offset by increased spending on R&D and periodic, heavy investments in acquired IPR&D, reflecting a strategic prioritization of long-term product pipeline growth over short-term earnings stability.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?